Xeris Biopharma Holdings (XERS) Enterprise Value (2020 - 2026)

Xeris Biopharma Holdings has reported Enterprise Value for 7 years, with the latest figure at -$111.8 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 91.22% year-over-year to -$111.8 million; the trailing twelve-month figure through Mar 2026 stood at -$111.8 million (down 91.22% YoY), and the FY2025 full-year result was -$111.0 million, down 55.04% from the prior year.
• Enterprise Value for Q1 2026 stood at -$111.8 million, down from -$111.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$58.4 million in Q1 2025, with the low at -$132.1 million in Q1 2022.
• Historically, Enterprise Value has averaged -$88.9 million across 5 years, with a median of -$87.4 million in 2024.
• Annual changes were most pronounced in 2023 — Enterprise Value surged 40.6% — and 2026, when it tumbled 91.22%.
• Xeris Biopharma Holdings' Enterprise Value stood at -$122.0 million in 2022, then surged by 40.6% to -$72.5 million in 2023, then rose by 1.15% to -$71.6 million in 2024, then sank by 55.04% to -$111.0 million in 2025, then decreased by 0.64% to -$111.8 million in 2026.
• The last three Enterprise Value figures came in at -$111.8 million (Q1 2026), -$111.0 million (Q4 2025), and -$91.6 million (Q3 2025), per Business Quant data.